The steady-state concentrations of cyclosporin G (0G37-325) (C5G) and six of its metabolites (GM1, GM9, GM4N, GM1c, GM1c9, GM19) were measured throughout the 12-h dosing interval in six renal transplant recipients receiving CsG as prophylaxis against acute cellular rejection. The mean 12-h whole-blood trough concentrations (g/L) were CsG, 131 ± 26; GM1, 79 ± 55; GM9, 110 ± 114; GM4N, 28 ± 18; GM1c, 31 ± 18; GM1c9, 216 ± 145; and GM1 9, 303 ± 217. The relative concentration of the primary metabolites (GM1, GM9, GM4N) remained 
Materials and Methods

Drugs and metabolites.
CsA and CsG were provided as gifts from Sandoz (East Hanover, NJ). CsG metabolites GM1, GM9, GM4N, GM1c, GM1c9, and GM19 were isolated by HPLC in our laboratory from urine from patients receiving the drug as previously described (11). Structure and purity were confirmed by fast atom bombardment mass spectroscopy and '3C nuclear magnetic resonance, and the purity of all metabolites was determined to be 97%.
Patients' samples. The following day (day 2) the subjects received a breakfast with moderate fat content and the procedure described above was repeated.
Compound
CsG
GM1
GM9 GM4N
GM1c
GM1 c9 GM19
To determine whether the type of formulation would alter the metabolism of the drug, the next morning, patients were switched to a soft gelatin capsule form of CsG (same mg content) and treated with the new formulation for 7 days, until steady-state was reattained. The day 1 and 2 sampling procedures described above were then repeated. In total, four sets of specimens were collected from each patient. All specimens were collected in tubes containing K-EDTA and stored at -70#{176}C until analysis. 
Results
Metabolite Concentrations
The steady-state 12-h trough concentrations of CsG and six of the major metabolites are shown in Fig. 1 The FPIA/HPLC ratios for individual patients ranged from 1.05 to 1.54, those for RJA/HPLC from 1.25 to 1.80. To determine whether the biases in the immunoassays could be accounted for by the cross-reactivity of the metabolites, the estimated bias for each assay was determined from the sum of the products of the cross-reactivity for each metabolite, as previously determined (16), and updated in a few instances due to further experimental validation in the present study, multiplied by the steady-state trough concentration for each metabolite as determined by HPLC. The results (Table 2) indicate that the calculated biases of 19% and 28%, respectively, for the FPIA and RIA procedures were not significantly different from the observed biases reported above.
DIscussIon
Previous studies by our laboratory indicated that the structure and activity of CsG metabolites are similar to those for CsA metabolites (11), making it probable that both drugs are metabolized in a similar manner. However, whether the relationships between the steadystate concentration of parent drug and metabolites are also similar was not known.
The data presented here indicate that the trough concentrations of the primary metabolites of CsG are lower, and those of the secondary metabolites, GM19 and GM1c9, are higher than the trough concentrations of the parent drug. This is in contrast to CsA: In renal transplant recipients, the primary metabolite AM1 is present at a higher concentration than parent CsA (20-23); also, the secondary metabolites AM19 and AM1c9 are at lower concentrations than the parent drug. Thus the biotransformation of primary metabolites to secondary metabolites may cccur more extensively with CsG than with CsA. The increase in GM19 and GM1c9 near the end of the dosing interval is most probably due to their conversion from primary metabolites, and may be amplified by enterohepatic circulation.
The latter has also been suggested for some of the CsA metabolites (24). We point out that only six stable renal transplant recipients were included in the study; whether the data will be applicable to other transplant categories remains to be determined. 
